Group 1 - The core viewpoint of the articles highlights the active performance of flu-related stocks in the A-share market, driven by a rising trend in acute respiratory infectious diseases in China, particularly influenza [1][2] - The National Influenza Center reported that 17 provinces in China have reached high flu levels, with expectations of peak activity in mid-December [1] - The dominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, with some H1N1 and B strains also present [1] Group 2 - Recent data indicates a significant increase in orders for antiviral medications, with orders for flu-specific drugs rising nearly ninefold compared to October, particularly for Maviroc and Oseltamivir [2] - Various pharmaceutical companies have shown notable stock price increases, with Guangdong Wannianqing rising over 11% and other companies like Yisheng Pharmaceutical and Jindike also experiencing substantial gains [3] - The overall supply of flu-related medications is reported to be sufficient, with recommendations for consumers to avoid panic buying [2]

Group 1 - The flu-related concept stocks experienced significant fluctuations, with Yingke Group hitting the daily limit up [1] - Haiwang Bio and Yisheng Pharmaceutical also reached the daily limit up, indicating strong market interest [1] - Yue Wannianqing saw an increase of over 10%, while companies like Guangji Pharmaceutical, Panlong Pharmaceutical, and Jindike also experienced gains [1]

New Stock Listings - Jingchuang Electric (920035) listed at an issuance price of 12.10 on December 2, 2025[1] - Tianpu Co., Ltd. (605255) is in the offer period from November 20 to December 19, 2025[1] Market Alerts - ST Suwu (600200) enters the delisting arrangement period starting December 9, 2025[1] - Jianglong Shipbuilding (300589) reported severe abnormal fluctuations[1] Recent Announcements - Multiple companies including Beida Pharmaceutical (000788) and ST Green Health (002868) have recent announcements regarding their stock activities[1] - A total of 30 companies have been flagged for abnormal trading activities in the last week[2]

谭华海先生已做好工作交接，其辞职不会影响公司相关工作的正常开展。谭华海先生在担任公司证券事 务代表期间恪尽职守、勤勉尽责，公司及董事会对谭华海先生在职期间为公司发展做出的努力和贡献表 示衷心感谢！ 公司董事会将根据《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第1号一一规范运作》等相关规定，尽快聘任符合任职资格的人员担任证券事务代表，协助公司董 事会秘书开展工作。 证券代码：688670 证券简称：金迪克 公告编号：2025-037 江苏金迪克生物技术股份有限公司 关于证券事务代表辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 江苏金迪克生物技术股份有限公司（以下简称"公司"）董事会于近日收到公司证券事务代表谭华海先生 提交的书面辞职报告，谭华海先生因个人原因申请辞去公司证券事务代表职务，辞职后不再担任公司任 何职务。谭华海先生的辞职报告自送达董事会之日起生效。 特此公告。 江苏金迪克生物技术股份有限公司 董事会 2025年12月2日 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-037 江苏金迪克生物技术股份有限公司 关于证券事务代表辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏金迪克生物技术股份有限公司（以下简称"公司"）董事会于近日收到公 司证券事务代表谭华海先生提交的书面辞职报告，谭华海先生因个人原因申请辞 去公司证券事务代表职务，辞职后不再担任公司任何职务。谭华海先生的辞职报 告自送达董事会之日起生效。 董事会 谭华海先生已做好工作交接，其辞职不会影响公司相关工作的正常开展。谭 华海先生在担任公司证券事务代表期间恪尽职守、勤勉尽责，公司及董事会对谭 华海先生在职期间为公司发展做出的努力和贡献表示衷心感谢！ 2025 年 12 月 2 日 公司董事会将根据《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定，尽快聘任符 合任职资格的人员担任证券事务代表，协助公司董事会秘书开展工作。 1 特此公告。 江苏金迪克生物技术股份有限公司 ...

南财智讯12月1日电，金迪克公告，公司董事会于近日收到证券事务代表谭华海先生提交的书面辞职报 告，谭华海先生因个人原因申请辞去公司证券事务代表职务，辞职后不再担任公司任何职务。谭华海先 生的辞职报告自送达董事会之日起生效。 ...

Core Insights - The flu activity in China is rapidly increasing, with the proportion of flu-like cases in southern provinces reaching 6.7% and northern provinces as high as 12%, significantly above previous years' levels [1] - The current flu outbreak is primarily driven by the H3N2 subtype, with a notable increase in demand for antiviral medications such as Oseltamivir and Baloxavir, leading to a surge in sales [1][2] - Domestic pharmaceutical companies, including Notai Bio, Kangyuan Pharmaceutical, and Jindike, are gaining market attention due to their antiviral product offerings and technological advancements [2][4] Industry Trends - The demand for flu medications has led to stock shortages in pharmacies, particularly for original research drugs [2] - Notai Bio has positioned itself competitively in the Oseltamivir market, with multiple drug registration certificates and an organized production line to meet the rising demand [2][3] - The market is transitioning from a dominance of Oseltamivir to a more diversified landscape with both traditional and innovative antiviral drugs being introduced [5] Company Highlights - Notai Bio has achieved significant sales growth for its Oseltamivir capsules, surpassing imported alternatives and establishing a strong online presence [3] - Kangyuan Pharmaceutical's products, such as the anti-viral injection and oral liquid, have shown resilience in sales despite overall revenue declines, indicating a strong growth potential in the flu season [4] - Jindike focuses on flu prevention with its quadrivalent flu vaccine, which has a production capacity of 20 million doses annually and is included in the national immunization program [4][5]

Group 1 - The flu activity in China is rapidly increasing, with sentinel hospitals in southern provinces reporting flu-like cases at 6.7%, up from 5.5% the previous week, and northern provinces reaching 12%, significantly higher than the same period from 2020 to 2023 [1] - The current flu strains include the H3N2 subtype, Victoria lineage, and H1N1, with significant antigenic variation leading to increased susceptibility in the population [1] - The demand for antiviral medications has surged, with sales of Oseltamivir increasing by 237% and Baloxavir by 180%, indicating a doubling of orders for flu-specific medications on platforms like Meituan and JD Health [1][2] Group 2 - Domestic pharmaceutical companies such as Nuotai Bio, Kangyuan Pharmaceutical, and Jindike are accelerating their entry into the flu treatment market, focusing on antiviral products [2] - Nuotai Bio has established itself as a competitive player in the Oseltamivir market, actively organizing production to ensure supply amid rising demand [2][3] - Kangyuan Pharmaceutical's products, including the antiviral injection and oral solution, have seen increased sales, with the oral solution contributing significantly to the company's revenue [4] Group 3 - The market is shifting from a dominance of Oseltamivir to a new phase where traditional and innovative treatments coexist, with new drugs like Marzula and Angladi being approved [5] - Companies with differentiated advantages and stable supply chains are expected to stand out in this competitive landscape, particularly those like Nuotai Bio that are deeply embedded in the global antiviral drug supply chain [5] - The upcoming flu peak is creating new growth opportunities for domestic pharmaceutical companies, driven by the increased demand for flu medications [5]

中国经济网北京11月28日讯 金迪克(688670.SH)今日收报27.40元，跌幅6.55%，总市值33.76亿元。 金迪克首次公开发行股票募集资金总额为12.14亿元，募集资金净额11.36亿元，较原拟募资净额少 4.64亿元。金迪克此前披露的招股书显示，该公司原拟募资16亿元，分别用于新建新型四价流感病毒裂 解疫苗车间建设项目、创新疫苗研发项目、补充流动资金及偿还银行借款项目。 金迪克于2021年8月2日在上交所科创板上市，公开发行新股2200万股，发行价格55.18元/股，保荐 机构为中信证券，保荐代表人为周游、赵岩。目前该股处于破发状态。 2023年5月19日，金迪克发布2022年年度权益分派实施公告。本次利润分配及转增股本以方案实施 前的公司总股本88,000,000股为基数，每股派发现金红利0.2元（含税），以资本公积金向全体股东每股 转增0.4股，共计派发现金红利17,600,000.00元，转增35,200,000股，本次分配后总股本为123,200,000 股。金迪克股权登记日2023年5月25日，除权（息）日2023年5月26日，新增无限售条件流通股份上市日 2023年5月26日，现金红 ...

Core Viewpoint - The market experienced mixed performance with the ChiNext index closing down 0.44%, while the influenza and organic silicon sectors surged, indicating a divergence in market sentiment driven by specific sectoral developments [1][4]. Group 1: Influenza Sector - The influenza sector saw a significant uptick, with flu-like cases in northern provinces rising to 7.0%, markedly higher than the same period in previous years [4]. - Sales of antiviral drugs, such as Oseltamivir, surged by 237% over the past week, indicating strong demand driven by rising flu cases [4]. - Jindike has completed the production season with 1.56 million doses of its quadrivalent flu vaccine approved for release, and is ramping up production capacity to 30 million doses [4]. Group 2: Organic Silicon Sector - The organic silicon sector experienced a boost following Dow Chemical's announcement of a 10%-20% price increase on major products starting December 10, which acted as a catalyst for domestic stocks [4]. - Companies like Hongbai New Materials and Chenguang New Materials saw their stocks hit the daily limit, while Dongyue Silicon Material rose over 10% [4]. - Smart money has already positioned itself in this sector, with Chenguang New Materials seeing a net inflow of 85.14 million yuan over the past ten trading days [4]. Group 3: Underperforming Sectors - The Hainan sector faced significant declines, with companies like Jingliang Holdings and Hainan Haiyao dropping nearly 7%, highlighting the lack of performance support for regional themes [4]. - The film and content industry also struggled, with Huanrui Century hitting the daily limit down and Shanghai Film falling nearly 7%, reflecting uncertainty in the content sector [4]. Group 4: Market Sentiment and Strategy - The overall trading volume decreased by 93.5 billion yuan compared to the previous day, indicating a cautious market sentiment and a tendency for rapid sector rotation [4]. - Investment strategies suggest focusing on the influenza sector for low-entry opportunities and the organic silicon sector for potential gains, while avoiding sectors lacking performance, policy support, or growth potential [5].